2016 Fiscal Year Final Research Report
Development of GD2-directed chimeric antigen receptor-modified T cells in pediatric patients with brain tumor
| Project/Area Number |
26860789
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Shinshu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | キメラ抗原受容体（CAR) / 遺伝子改変T細胞療法 / 小児脳腫瘍 / 網膜芽細胞腫 / ボリノスタット |
|---|
| Outline of Final Research Achievements |
We found that pediatric brain tumors (medulloblastoma and glioblastoma) and retinoblastoma express GD2 highly. Next, we manufactured GD2-specific chimeric antigen receptor-transducted T cell (GD2 CAR-T cell) with piggyBac transposon system which is a non-viral gene transduction method. GD2 CAR T cell killed GD2-positive tumor cell lines dramatically in vitro. We searched combination drugs to enhance the antirtumor ability of the GD2 CAR T cell. We found that histone deacetylase inhibitors, vorinostat, can enhance the antitumor ability of the GD2 CAR T cell.
|
| Free Research Field |
小児血液腫瘍
|
